Drugs / Culturelle
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04373512 | May 2020 → Feb 2025 | spinal cord injury | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06636669 | Aug 2025 → Jun 2027 expected | immune dysregulation, neurodevelopmental defects, and colitis, periprosthetic joint infection | Boston Medical Center | Enrolling by invitation | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Culturelle | “Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.” NCT06636669 ↗ |